Pulmonary–Respiratory | Mapi Research Trust

Lead text placeholder. Lorem ipsum dolor sit amet, consectetur adipisicing elit.

Articles

2017. Pavel ME et al. – Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
2017. Miles C et al. – Barriers and facilitators of effective self-management in asthma: Systematic review and thematic synthesis of patient and healthcare professional views
2017. Cooper WA et al. – Intra- and inter-observer reproducibility assessment of PD-L1 biomarker in non-small cell lung cancer (NSCLC)
2016. Linneberg A et al. – Burden of allergic respiratory disease: A systematic review
2016. Morélot-Panzini C et al. – Real-life assessment of the multidimensional nature of dyspnoea in COPD patients
2016. Medic G et al. – Efficacy and safety of aclidinium/formoterol versus tiotropium in COPD: Results of an indirect treatment comparison
2016. de La Loge C et al. – Relationship between FEV1 and patient-reported outcomes changes: Results of a meta-analysis of randomized trials in stable COPD
2016. Chen YJ et al. – Exacerbations, health services utilization, and costs in commercially-insured COPD patients treated with nebulized long-acting β2-agonists
2015. Ismaila AS et al. – Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: A systematic review and network meta-analysis
2015. Huisman EL et al. – Comparative efficacy of combination bronchodilatator thrapies in COPD: A network meta-analysis
2014. Karabis A et al. – Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: An analysis over 5 years
2013. Cope S et al. – Comparative efficacy of long-acting bronchodilators for COPD – A network meta-analysis
2013. Chouaid C et al. – Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: A prospective cross-sectional patient survey in a real world setting
2013. Lapillonne A et al. – Development of a questionnaire to assess the impact on parents of their infant’s bronchiolitis hospitalization
2013. Karabis A et al. – Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: A systematic review and network meta-analysis
2012. Lapillonne A et al. – Impact on parents of bronchiolitis hospitalization of full-term, preterm and congenital heart disease infants
2012. Littlewood KJ et al. – A network meta-analysis of the efficacy of inhaled antibiotics for chronic pseudomonas infections in cystic fibrosis
2012. Verduyn SC et al. – Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non-small cell lung cancer patients in The Netherlands
2012. Cope S et al. – Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: A study level and a patient level network meta-analysis
2012. Cope S et al. – Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: A patient level mixed treatment comparison
2012. Cope S et al. – Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol/budesonide or salmeterol/fluticasone for COPD: A network meta-analysis
2011. Aguilaniu B et al. – Disability related to COPD tool (DIRECT): Towards an assessment of COPD-related disability in routine practice
2011. Cope S et al. – Comparative efficacy of indacaterol 150 µg and 300 µg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease – A network meta-analysis
2009. Perez T et al. – Validity, reliability, and responsiveness of a new short Visual Simplified Respiratory Questionnaire (VSRQ) for health-related quality of life assessment in chronic obstructive pulmonary disease
2003. Stǻhl E et al. – Health-related quality of life in asthma studies. Can we combine data from different countries?

Posters & Presentations

2017. ISPOR European Congress – Impact of different baseline definitions on the incidence of relevant outcomes associated with cancer following an advanced non-small cell lung cancer (NSCLC) diagnosis
2016. IASLC World Conference on Lung Cancer – Have we shifted the therapeutic innovation frontier? A US assessment of advanced non–small cell lung cancer (advNSCLC)
2016. ISPOR European Congress – Baseline Characteristics and Survival of Patients Diagnosed with Advanced NSCLC in Sweden Between 2006 and 2013, Matched (1:4) to a Comparison Cohort from the General Population
2016. ISOQOL Annual Conference – Standardised Translation of the Bronchiectasis Health Questionnaire (BHQ) into Eleven Languages
2016. ERS International Congress – Comparative Efficacy of Umeclidinium/Vilanterol versus LABA/LAMA Therapies in COPD: A Network Meta-Analysis
2016. ERS International Congress – Translation of the Bronchiectasis Health Questionnaire Using Validated Methods
2016. ISPOR Annual International Meeting – Value of Innovation in Oncology Treatments for Patients in Sweden with Advanced or Metastatic Non-Small Cell Lung Cancer (advNSCLC)
2015. ISPOR European Congress – Psychometric Validation of the Multidimensional Dyspnea Profile (MDP) Questionnaire
2015. ISPOR Annual International Meeting – Usability Testing of the Web-Based Versions of the Standardised Asthma Quality of Life Questionnaire for 12 years and Older (AQLQ(S)+12) and the Asthma Control Questionnaire (ACQ-6)
2015. ISPOR Annual International Meeting – A Review of Health-Related Quality of Life (HRQL) Claims in Labels of Asthma Products – Can We Consider the Asthma Quality of Life Questionnaire (AQLQ) as a Potentially Acceptable Measure for Qualification?
2014. ISPOR European Congress – Comparative efficacy of umeclidinium bromide versus other long-acting anticholinergic monotherapies as treatments for COPD patients
2014. ISPOR European Congress – Systematic Review of Observational Studies and RCTs of Omalizumab in Severe Persistent Allergic Asthma and Meta-Analysis Feasibility Assessment
2014. ISOQOL Annual Conference – Development of E-Versions of the Asthma Quality of Life Questionnaire (Standardised) [AQLQ(S)] in Twenty (20) Languages for Use on Handheld Devices
2014. ERS Annual Meeting – Comparative assessment of umelidinium/vilanterol (UMEC/VI) combination therapy among symptomatic COPD patients
2013. ISPOR European Congress – Evaluating Whether Inconsistencies Are Present in a Mixed Treatment Comparison of Trough Forced Expiratory Volume in 1 Second at 12 Weeks
2013. ISPOR European Congress – Network Meta-Analysis with Fractional Polynomials for Repeated Trough FEV1 Measures in COPD: Aclidinium Bromide 400 μg Bid Versus Tiotropium 18 μg QD
2013. ISPOR European Congress – Development of an Interviewer-Administered Version of the Asthma Control Questionnaire (ACQ-IA) for 6-10 Year Old Patients in 11 Languages
2013. ISPOR European Congress – Efficacy of Inhaled Antibiotics in CF Patients with Chronic P. Aeruginosa Infection: A Network Meta-Analysis
2013. ISPOR European Congress – Addressing Heterogeneity in Baseline Risk of COPD Exacerbations Using Meta-Regression
2013. ISPOR European Congress – Patient-Reported Outcome (PRO) Claims in Products Approved for Chronic Obstructive Pulmonary Diseases (COPD) in Europe and in the USA
2013. ISPOR European Congress – Economic Evaluation of Ceftobiprole Compared to a Combination of Linezolid with Ceftazidime in the Management of Hospitalised Pneumonia in Scotland
2013. ISPOR European Congress – Assessing Non-Inferiority of Aclidinium Bromide 400 μg Bid Versus Tiotropium 18 μg and 5 μg QD in Patients with Chronic Obstructive Pulmonary Disease (COPD) by Means of a Network Meta-Analysis
2013. ICPE Meeting – Prevalence and Incidence of Idiopathic Pulmonary Fibrosis in UK Healthcare Databases, GPRD and THIN; the Need for an IPF Registry
2013. ISPOR Annual International Meeting – Economic Evaluation of Aclidinium Bromide in the Management of Moderate-to-Severe COPD
2013. ISPOR Annual International Meeting – Patient-Reported Outcomes (PROs) Claims in Products Indicated for Treatment of Non-Small Cell Lung Carcinoma and Approved in Europe and in the United States
2013. ISPOR Annual International Meeting – Development of the 6-10 Year Interviewer-Administered Version of the Asthma Control Questionnaire (ACQ-IA) in Spanish for Guatemala and Peru
2012. ISPOR European Congress – Dual bronchodilation with indacaterol and tiotropium in combination versus triple therapy, fixed-dose combinations, and monotherapy in COPD. A network meta-analysis of FEV1
2012. ISPOR European Congress – Comparative efficacy of Aclidinium Bromide 400 µg bid versus Tiotropium 18 µg and 5 µg QD as maintenance bronchodilatator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD): A network meta-analysis
2012. ISPOR European Congress – Efficacy of Ceftaroline Fosamil and Other Intravenous Antibiotics in the Treatment of Community-Acquired Pneumonia (CAP): A Network Meta-Analysis (NMA)
2012. CHEST – The association between rescue medication use and future exacerbations in COPD – A retrospective analysis of randomized controlled trials
2012. ISPOR Asia-Pasific Conference – The Copyright of Translations of PRO Instruments: The Case of Instruments Used in Lung Diseases
2012. ISPOR Asia Pacific Conference – Clinical COPD Questionnaire (CCQ): Is There a Need to Develop a Specific English Version for the Philippines and India
2012. ISPOR Annual International Meeting – Evaluating Meaningful Change on the Lung Cancer Symptom Scale in Small Cell Lung Cancer: Results from a Phase III Clinical Trial
2012. ISPOR Annual International Meeting – Acceptability of the Self-Administered Computerized (SAC) Versions of the Baseline/Transition Dyspnea Indexes (BDI/ TDI) for Patients with COPD from Seven Countries
2012. ATS Conference – Comparative efficacy of indacaterol 75 µg versus fixed-dose combinations of formoterol + budesonide or salmeterol + uticasone for the treatment of chronic obstructive pulmonary disease
2011. ISPOR European Congress – Importance of Collaboration with Developers in the Clarification of Concepts: A Case Study with the University of California, San Diego (UCSD) Shortness of Breath Questionnaire (SOBQ)
2011. ISPOR European Congress – Testing of a Conceptual Model of Asthma in Adolescents
2011. ISPOR European Congress – Quality of Life in Small Cell Lung Cancer: Results of an Open-Label Phase III Clinical Trial
2011. ISPOR Annual International Meeting – Overview of Primary Endpoints, Progression Free-Survival (PFS) and Overall Survival (OS) for Non-Small Cell Lung Cancer (NSCLC): Their Value in Treatment Decisions and Patient Care
2010. ISPOR European Congress – Testing the Usability and Language of ePRO Translations during Linguistic Validation: Cognitive Debriefing on eDevice Vs. Print Out of Screenshots
2010. ISPOR European Congress – Mixed Treatment Comparison of Bevacizumab-Based Therapies Relative to Doublet-Chemotherapy Combinations to Estimate the Relative Efficacy in Progression Free Survival for Treatment of First-Line Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
2009. ISOQOL Annual Conference – Is it Necessary to Develop English Versions of the Asthma Quality of Life Questionnaire (AQLQ)?
2009. ISPOR European Congress – Item Selection and Scoring Definition of a Disease-Specific Instrument to Assess the Handicap in Chronic Obstructive Pulmonary Disease (COPD) Patients, For Use in Clinical Routine Practice
2009. ISPOR Annual International Meeting – Development of a Specific Questionnaire Assessing the Impact on Parents of an Infant’s Bronchiolitis Hospitalization
2008. ISPOR European Congress – Use of an Electronic Diary in 55 Countries: What are the Challenges?
2008. ISPOR European Congress – Symptoms and Impact of Symptoms as Reported by Asthma Patients
2008. ISPOR European Congress – How Congruent Are Patients and Clinician Models of Asthma Control? – Preliminary Finding from a Qualitative Study
2008. ISPOR Annual International Meeting – Treatment Satisfaction Questionnaires in Asthma and Other Chronic Diseases
2006. ISPOR European Congress – Measuring the impact of COPD on Patients’ Lives in an International Study
2005. ISPOR European Congress – Patient-Reported Impact of Cough and Sputum in Chronic (Obstructive) Bronchitis – Simultaneous Development of the Self-Administered CASA-Q
2005. ISPOR European Congress – Impact of Dyspnoea on Daily Activities in COPD Patients – Development and Testing of a New Questionnaire for Clinical Practice and Clinical Trials.